Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 1/20 | 0.52 |
| ▸ | CCR8 | P51685 | 1/20 | 0.52 |
| ▸ | CTSS | P25774 | 2/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.46 |
| ▸ | TRPV3 | Q8NET8 | 2/20 | 0.44 |
| ▸ | KDM1A | O60341 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.41 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 1/20 | 0.39 |
| ▸ | KMO | O15229 | 1/20 | 0.39 |
| ▸ | METAP2 | P50579 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4936538 | 0.89 | CCR1 (0.44) | CCR1CCR8CTSSCYP2A6TRPV3 | |
| SCHEMBL2615262 | 0.88 | CTSS (0.60) | CCR1CCR8CTSSCYP2A6KDM1A | |
| SCHEMBL26233974 | 0.84 | CCR1 (0.54) | CCR1CCR8CYP2A6TGFBR1METAP2 | |
| SCHEMBL2615265 | 0.84 | CCR1 (0.54) | CCR1CCR8CYP2A6TRPV3HSD11B1 | |
| SCHEMBL18758860 | 0.83 | CYP2A6 (0.53) | CCR1CCR8CTSSCYP2A6TRPV3 | |
| SCHEMBL13483700 | 0.80 | CCR1 (0.71) | CCR1CCR8CYP2A6TGFBR1METAP2 | |
| SCHEMBL19072770 | 0.80 | CTSS (0.47) | CTSSTRPV3KDM1ACTSKKMO | |
| SCHEMBL19072771 | 0.80 | CTSS (0.47) | CTSSTRPV3KDM1ATGFBR1 | |
| SCHEMBL4451357 | 0.79 | CTSS (0.46) | CTSSTRPV3KDM1AKMO | |
| SCHEMBL19248536 | 0.77 | IDH1 (0.47) | CTSSTGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150307496-A1 | NOVEL TRICYCLIC 3,4-DIHYDRO-2H-PYRIDO[1,2-a]PYRAZINE-1,6-DIONE DERIVATIVES AS GAMMA SECRETASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2015-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150307496-A1 | NOVEL TRICYCLIC 3,4-DIHYDRO-2H-PYRIDO[1,2-a]PYRAZINE-1,6-DIONE DERIVATIVES AS GAMMA SECRETASE MODULATORS | BACE1, BACE2, PSEN1 | CCR1 4250/4885CCR8 4770/4885CTSS 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.